Wuhan Hiteck Biological Pharma (300683.SZ) has obtained the drug registration certificate for injectable Isavuconazonium Sulfate.

Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for injection of isavuconazole sulfate. Isavuconazole sulfate for injection is suitable for adult patients with invasive aspergillosis, invasive mucormycosis, and is classified as a Category B type of National Medical Insurance. Isavuconazole sulfate is a prodrug of the triazole antifungal drug isavuconazole. Isavuconazole works by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase (which is responsible for converting lanosterol to ergosterol) to block the synthesis of ergosterol, a key component of the fungal cell membrane. This leads to the accumulation of methylated sterol precursors in the cell membrane and depletion of ergosterol, weakening the structure and function of the fungal cell membrane. Isavuconazole demonstrates activity against most strains of fungi such as Aspergillus, Fusarium, Mucomycetes, and certain molds in vitro and in clinical infections. Obtaining the "Drug Registration Certificate" for isavuconazole sulfate for injection signifies that the company is qualified to sell the drug in the domestic market, which will enrich the company's product line, enhance its competitiveness in the field of anti-infectives, and have a positive impact on the company's future business development.